We are thrilled to announce that the first patient was dosed in our Phase I/II study investigating our product candidate TAC01-CLDN18.2 in solid tumors positive for claudin 18.2. “There are currently no other approved treatment modalities against CLDN18.2,” said Deyaa Adib, MD, Chief Medical Officer. #oncology #cancerresearch #clinicaltrials #celltherapy Learn more at https://lnkd.in/eN6dhRgt
关于我们
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you. For more information about Triumvira career opportunities, please see our Careers web page at: https://triumvira.com/contact-us/careers/
- 网站
-
https://triumvira.com/
Triumvira Immunologics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Austin，Texas
- 类型
- 私人持股
- 创立
- 2015
- 领域
- Immunology、Oncology、Cell and Gene Therapy、T cell Antigen Coupler、Clinical Developement和Partnerships
地点
Triumvira Immunologics, Inc.员工
动态
-
Triumvira Immunologics, Inc. will be presenting updated clinical data on our TACTIC-3 program at the Society for Immunotherapy of Cancer (SITC) Spring Scientific, Cellular Therapy and Solid Tumors Conference in San Diego, California, March 12-14. “These interim findings further reinforce the potential of our TAC technology to deliver safe and effective cell therapies for patients with Claudin 18.2+ advanced solid tumors,” said Robert Williamson, President of Triumvira Immunologics. Check out the full news release here: https://prn.to/3DLV7Yb #Immunotherapy #CellTherapy #CancerResearch
-
-
Clinical updates from our TACTIC-3 trial were included in BioWorld News' “In the clinic Jan. 28, 2025” roundup article. Our TAC01-CLDN18.2 cell therapy candidate demonstrated promising results in advanced solid tumors, including a confirmed partial response in stage IV pancreatic cancer. With a favorable safety profile and a 70% disease control rate, we're making meaningful progress in addressing significant unmet medical needs. Check out the article here: https://bit.ly/4gTgPaa #CellTherapy #Immunotherapy
-
-
On World Cancer Day, we take a moment to recognize the incredible resilience that defines the cancer community. The courage of patients, support provided by caregivers, and dedication of researchers are driving forces in our mission to defeat cancer. #Immunotherapy #CellTherapy #CancerResearch
-
-
Clinical updates from our Phase I/II TACTIC-3 study. We’re pleased to share promising results for our novel TAC-T cell candidate therapy targeting Claudin 18.2 positive solid tumors. Highlights include: ? Favorable safety and tolerability profile ? Confirmed on-going partial response in a pancreatic cancer patient ? Additional partial response observed in heavily pretreated esophageal cancer patient Check out the full news release here: https://prn.to/3WwRHPp #Immunotherapy #CellTherapy #CancerResearch
-
-
We are happy to share that clinical data from our TACTIC-3 trial will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Ecaterina Dumbrava of MD Anderson Cancer Center. See the following link for additional details: https://bit.ly/4hnCNTn #Immunotherapy #CellTherapy #CancerResearch
-
-
At Triumvira Immunologics, Inc., we’re advancing two approaches to cell therapy in our fight against cancer. Autologous therapy harnesses the power of the patient’s own immune cells, creating a personalized treatment. Our allogeneic approach will offer readily available treatment options for patients in need using healthy donor cells. To learn more about our TAC platform and on-going trials visit our website: https://bit.ly/48mZX7O #Immunotherapy #CellTherapy #CancerResearch
-
-
As we look ahead to 2025, we’re grateful for a year of significant progress in our revolutionary cell therapies. Our commitment to transforming gastric cancer care is stronger than ever, thanks to our dedicated team, partners, and patients in our trials. Here’s to a great year ahead with continued momentum in advancing life-changing cell therapies. #CellTherapy #CancerResearch #Innovation
-
-
As we reflect on 2024, we're thankful for our dedicated team, partners, and supporters who share our commitment to advancing the cell therapy treatment landscape. Your collaboration and trust inspire us every day. We look forward to continuing our mission of developing life-changing treatments in the year ahead. #Immunotherapy #CellTherapy #CancerResearch
-
-
Did you know that the average age of diagnosis for gastric cancer is 68? The American Cancer Society latest data reveals significant insights about the current outlook for gastric cancer in the United States. We at Triumvira Immunologics, Inc. are dedicated to discovering revolutionary cell therapies to reduce the burden of disease for those with gastric cancer. #CancerAwareness #Healthcare #CellTherapy #CancerResearch
-